Kennis & ervaring
Specialisme / subspecialisme: Bot- en Weke Delen Sarcomen
Werkervaring
1993-1998: opleiding tot kinderarts Wilhelmina Kinderziekenhuis, Utrecht
1998-2002: Fellowship Kinderoncologie AMC, Amsterdam
1998-2004: Promotie onderzoek naar tumorpredispositie bij kinderen, Universiteit van Amsterdam
2002-2014: Staflid Kinderoncologie AMC, Amsterdam
2014-2018: Hoofd afdeling Kinderoncologie AMC, Amsterdam
2015-heden: Staflid afdeling Solide Tumoren Prinses Máxima Centrum
Wetenschappelijk
Opleiding
2004 Phenotypic abnormalities in childhood cancer patients; clues for molecular defects?
2014-2018: PI Sarcoma Research AMC, Universiteit van Amsterdam
2018-heden: co-PI Sarcoma Research Prinses Máxima Centrum
Publicaties
Mijn publicaties op pubmed lees je hier.
Prevalence and patterns of morphological abnormalities in patients with childhood cancer.
Merks JH, Ozgen HM, Koster J, Zwinderman AH, Caron HN, Hennekam RC.
JAMA. 2008 Jan 2;299(1):61-9.
Parameningeal rhabdomyosarcoma in pediatric age: results of a pooled analysis from North American and European cooperative groups.
J.H.M. Merks, G.L. De Salvo, C. Bergeron, G. Bisogno, A. De Paoli, A. Ferrari, A. Rey, O. Oberlin, M.C.G. Stevens, A. Kelsey, J. Michalski, D.S. Hawkins, J.R. Anderson.
Annals of Oncology, 2014 Jan;25(1):231-6.
Adverse events of local treatment in long-term head and neck rhabdomyosarcoma survivors after external beam radiotherapy or AMORE treatment.
Schoot RA, Slater O, Ronckers CM, Zwinderman AE, Balm AJM, Hartley B, Van den Brekel MW, Gupta S, Saeed P, Gajdosova E, Pieters BR, Gaze MN, Mandeville HC, Davila Fajardo R, Ch’ing Chang Y, Gains JE, Strackee SD, Dunaway D, Abela C, Mason C, Smeele LE, Chisholm JC, Levitt GA, Kremer LCM, Grootenhuis MA, Maurice-Stam H, Stiller CA, Hammond P, Caron HN, Merks JH.
European Journal of Cancer, 2015 Jul;51(11):1424-34
Open-label, multicentre, randomised, phase II study of the EpSSG and the ITCC evaluating the addition of bevacizumab to chemotherapy in childhood and adolescent patients with metastatic soft tissue sarcoma (the BERNIE study).
Chisholm JC*, Merks JHM*, Casanova M, Bisogno G, Orbach D, Gentet JC, Thomassin-Defachelles AS, Chastagner P, Lowis S, Ronghe M, McHugh K, van Rijn RR, Hilton M, Bachir J, Fürst-Recktenwald S, Geoerger B, Oberlin O; European paediatric Soft tissue sarcoma Study Group (EpSSG) and the European Innovative Therapies for Children with Cancer (ITCC) Consortium.(*1st authors equally contributed).
Eur J Cancer. 2017 Sep;83:177-184
Addition of dose-intensified doxorubicin to standard chemotherapy for rhabdomyosarcoma (EpSSG RMS 2005): a multicentre, open-label, randomised controlled, phase 3 trial.
Bisogno G, Jenney M, Bergeron C, Gallego Melcón S, Ferrari A, Oberlin O, Carli M, Stevens M, Kelsey A, De Paoli A, Gaze MN, Martelli H, Devalck C, Merks JH, Ben-Arush M, Glosli H, Chisholm J, Orbach D, Minard-Colin V, De Salvo GL; European paediatric Soft tissue sarcoma Study Group.
Lancet Oncol. 2018 Aug;19(8):1061-1071. doi: 10.1016/S1470-2045(18)30337-1. Epub 2018 Jun 22.
Contactgegevens